Multiunit Particulate Systems: A Current Drug-Delivery Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Multiunit Particulate Systems: A Current Drug-Delivery Technology
The current review describes the role and selection of excipients, pellet core, coating materials, and compression with various cushioning agents.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 60-66

22. T.E. Beckert, K. Lehmann, and P.C. Schmidt, Int. J. Pharm. 143 (1), 13–23 (1996).

23. G. Ragnarsson et al., Drug Dev. Ind. Pharm. 13 (9–11), 1495–1509 (1987).

24. G.P. Millili and J.B. Schwartz, Drug Dev. Ind. Pharm. 16 (8), 1411–1426 (1990).

25. B. Johansson et al., Int. J. Pharm. 117 (1), 57–73 (1995).

26. F. Nicklasson and G. Alderborn, Pharm. Res. 17 (8), 947–952 (2000).

27. Y.S. Habib, L.L. Augsburger, and R.F. Shangraw, Int. J. Pharm. 233 (1–2), 67–83 (2002).

28. S.R. Bechard and J.C. Leroux, Drug Dev. Ind. Pharm. 18 (18), 1927–1944 (1992).

29. V.S.N.M. Dwibhasyam, Ind. J. Pharm. Sci. 70 (5), 555–564 (2008).

30. A. Tuton, J. Grasjo, and G. Alderborn, Eur. J. Pharm. Sci. 19 (5), 333–344 (2003).

31. M. Celik and L. Maganti, Drug Dev. Ind. Pharm. 20 (20), 3151–3173 (1994).

32. S.R. Bechard and J.C. Leroux, Drug Dev. Ind. Pharm. 18 (18), 1927–1944 (1992).

33. J.J. Torrado and L.L. Augsburger, Int. J. Pharm. 106 (2), 149–155 (1994).

34. H. Haubitz, W. Mehnert, and K.H. Fromming, Pharm. Ind. 58 (1), 83–86 (1996).

35. L. Stubberud et al., Pharm. Dev. Technol. 3 (2), 141–151 (1998).

36. H. Yuasa et al., S.T.P. Pharma Sci. 11 (3), 221–228 (2001).

37. T. Yao et al., Chem. Pharm. Bull. 46 (5), 826–830 (1998).

38. G.J. Vergote et al., Eur. J. Pharm. Sci. 17 (3), 145–151 (2002).

39. J. Hogan, "Coating of tablets and multiparticulates," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, Edinburgh, 2002), pp.441–448.

40. R.K. Chang and E.M. Rudnic, Int. J. Pharm. 70 (3), 261–270 (1991).

41. K. Lehmann, H.U. Petereit, and D. Dreher, Pharm. Ind. 55 (10), 940–947 (1993).

42. A. Onions, Manuf. Chem. 57 (3), 55–59 (1986).

43. A. Onions, Manuf. Chem. 57 (4), 66–67 (1986).

44. J.T. Heinamaki et al., Pharm. Ind. 57 (1), 68–71 (1995).

45. M.E. Aulton, Int. J. Pharm. Technol. Prod. Manuf. 3 (1), 9–16 (1982).

46. L.A. Felton et al., S.T.P. Pharma Sci. 7 (6), 457–462 (1997).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here